- Agenus Inc. (AGEN) recently signed a collaboration agreement with Bristol-Myers Squibb (BMY) that has helped spark a large rally in the stock.
- The deal marks six active collaborations, providing the immuno-oncology concern with more shots on goal than just about any other clinical-stage biotech.
- With $200 million upfront from Bristol-Myers, a rolling BLA submission for its most advanced asset (balstilimab), and 15 clinical-stage programs, Agenus merited a deeper dive.
- A full investment analysis follows in the paragraphs below.
For further details see:
Agenus: What Now